Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liping Su

Showing results (241-250 of 254) with videos related to

Pageof 26
Sort By:
British Journal of Haematology|September 27, 2024
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysisJing Liu, Fenghua Gao, Tingting Zhang, et al.
Oncotarget|July 8, 2016
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149Lei Zhang, Sisi Jia, Yangyang Ma, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 27, 2014
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma]Jianqiu Wu, Yongping Song, Liping Su, et al.
Biomarker Research|February 7, 2023
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter studyJie Zha, Qinwei Chen, Jingjing Ye, et al.
Scientific Reports|October 21, 2020
Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse modelsWei-Wen Lim, Ben Corden, Benjamin Ng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma]Jifeng Feng, Jianqiu Wu, Yongping Song, et al.
Biomarker Research|January 3, 2025
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphomaJie Zha, Qinwei Chen, Wei Zhang, et al.
BMC Cancer|July 28, 2016
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional studyJianqiu Wu, Yongping Song, Liping Su, et al.
Cancer Science|October 11, 2018
Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failureShaoxuan Hu, Yuqin Song, Xiuhua Sun, et al.
Annals of Hematology|December 19, 2023
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trialHuixing Zhou, Yafei Wang, Jiao Chen, et al.
Pageof 26

Showing results (241-250 of 254) with videos related to

Sort By:
Pageof 26
British Journal of Haematology|September 27, 2024
Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysisJing Liu, Fenghua Gao, Tingting Zhang, et al.
Oncotarget|July 8, 2016
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149Lei Zhang, Sisi Jia, Yangyang Ma, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|May 27, 2014
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma]Jianqiu Wu, Yongping Song, Liping Su, et al.
Biomarker Research|February 7, 2023
Differences in clinical characteristics and outcomes between patients with grade 3a and grades 1-2 follicular lymphoma: a real-world multicenter studyJie Zha, Qinwei Chen, Jingjing Ye, et al.
Scientific Reports|October 21, 2020
Interleukin-11 is important for vascular smooth muscle phenotypic switching and aortic inflammation, fibrosis and remodeling in mouse modelsWei-Wen Lim, Ben Corden, Benjamin Ng, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 25, 2014
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma]Jifeng Feng, Jianqiu Wu, Yongping Song, et al.
Biomarker Research|January 3, 2025
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphomaJie Zha, Qinwei Chen, Wei Zhang, et al.
BMC Cancer|July 28, 2016
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional studyJianqiu Wu, Yongping Song, Liping Su, et al.
Cancer Science|October 11, 2018
Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failureShaoxuan Hu, Yuqin Song, Xiuhua Sun, et al.
Annals of Hematology|December 19, 2023
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trialHuixing Zhou, Yafei Wang, Jiao Chen, et al.
Pageof 26